

Drug Monograph

Drug/Drug Class: **Aminosyn II™ (isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, glutamic acid, histidine, proline, serine, n-acetyl-tyrosine and glycine) injection / Biologic Agent**

Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Aminosyn II™ is available as a 500 ml container of 7% and a 500 ml container and 1000 ml container of 8.5%, sulfite-free, amino acid injection.
Manufacturer:	Hospira, Inc., Lake Forest, IL 60045 USA
Indications:	Aminosyn II™, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate
Costs:	\$10 per 500 ml container of 7% and 8.5% and \$8 per 1000 ml container of 8.5% Aminosyn II™ Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.
 Date: March 3, 2015